Dr. Jedd D. Wolchok on PD1 Pathway

[erinmay22]

Here is a video with Dr Wolchok on PD1 Pathway, Activity of Novel Agent Nivolumab as Potential Predicative Target

Jedd D. Wolchok, MD, PhD, 2013-2014 Chair for ASCO’s Scientific Program Committee, provides a illustrative overview of the role of the PD-1 pathway and its ligand, PDL-1, across disesase sites—particularly kidney and non-small cell lung cancers, as well as melanoma. Activity of the novel agent, nivolumab, as well use of the PD-1 pathway as a potential predicative target also are discussed. Regarding immunotherapy, Dr. Wolchok lends his wisdom regarding its role in cancer treatment and in durable disease regression.

Follow link for video: http://chicago2013.asco.org/dr-jedd-d-wolchok-pd1-pathway-activity-novel-agent-nivolumab-potential-predicative-target?et_cid=31868877&et_rid=555962827&linkid=http%3a%2f%2fchicago2013.asco.org%2fdr-jedd-d-wolchok-pd1-pathway-activity-novel-agent-nivolumab-potential-predicative-target

[SusanB]

Thank you, Erin.

[Author]

Posts